Registry of Subjects at Risk of Pancreatic Cancer

Launched by ASSOCIAZIONE ITALIANA PER LO STUDIO DEL PANCREAS · Sep 17, 2019

Keywords

ClinConnect Summary

The "Registry of Subjects at Risk of Pancreatic Cancer" is a clinical trial that aims to learn more about pancreatic cancer and the factors that might increase the risk of developing this disease, especially in people who have a family history or specific genetic conditions. This study is focused on individuals who have close family members with pancreatic cancer or who carry certain genetic mutations linked to the disease. The trial is currently recruiting participants aged between 65 to 74 years and 29 to 219 years, and it welcomes individuals of all genders.

To be eligible for this study, you might qualify if you have at least two relatives with pancreatic cancer, especially if one of them is a close family member like a parent or sibling. You may also qualify if you have specific genetic mutations (like BRCA1 or BRCA2) and a family history of pancreatic cancer, or if you belong to certain hereditary syndromes. Participants can expect to be part of a registry where their health will be monitored over time, helping researchers to understand better how these factors relate to pancreatic cancer. It's important to note that pregnant individuals are not eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria to enter the registry:
• • individuals with at least two relatives suffering from pancreatic cancer, with at least 1 first-degree and until the third-degree
• • subjects with known genetic mutation of BRCA2, BRCA1, p16, PALB2 with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer
• • subjects suffering from FAMMM Syndrome
• • subjects suffering from Peutz-Jeghers Syndrome
• • subjects suffering from PRSS-1- or CFTR- or SPINK-1- related pancreatitis
• • subjects suffering from Lynch syndrome with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer
• Inclusion criteria to join the "radiologic follow-up":
• • 45 years or 10 years younger than the youngest index case of pancreatic cancer in the family for familial cases
• • 40 years or 5 years younger than the youngest index case of pancreatic cancer for subjects suffering from hereditary/genetic pancreatitis, Lynch syndrome, or carrying a known BRCA 1/2, PALB2, p16 genetic mutation with familiarity for pancreatic cancer
• • 30 years for subjects suffering from FAMMM, Peutz-Jeghers syndrome
• Exclusion Criteria:
• • - pregnancy